RSS
29 Nov 2019

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) for Breast Cancer Indication

Author: admintech | Filed under: Press Release

SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ — On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company’s lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC)…

This entry was posted on Friday, November 29th, 2019 at 7:22 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»